Biotechnology News and Research

RSS

DCVax therapeutic cancer vaccine manufacturing process receives patent approval

Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") announced today that the US Patent and Trademark Office has allowed its patent application on a system for automation of the initial stages of the manufacture of the Company's DCVax® therapeutic cancer vaccines.

4 Dec 2009

APCER Pharma Solutions' webinar on 2010 FDA drug safety and pharmacovigilance initiatives

APCER Pharma Solutions, Inc.’s webinar on 2010 FDA drug safety and pharmacovigilance initiatives gave more than 250 professionals in the life sciences-related industries the jump start they needed to prepare for important changes next year.

4 Dec 2009

Neurologix completes Phase 2 clinical trial of Parkinson’s study

Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced the completion of all planned surgeries in an ongoing Phase 2 clinical trial of the company’s gene transfer approach to the treatment of advanced Parkinson’s disease.

4 Dec 2009

Genzyme announces reopening of enrollment in its Pompe disease ATAP program

Genzyme Corporation announced today that it will reopen enrollment in the Alglucosidase Alfa Temporary Access Program (ATAP), a program which provides access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme™ (alglucosidase alfa). Genzyme and the FDA have also agreed on a path toward approval of Lumizyme.

4 Dec 2009

Kyto advancing with a program for humanization of the mAbTCR23 antibody

Kyto Biopharma Inc., is a biotechnology company focused on developing monoclonal antibody and oligonucleotide targeting therapeutics based on a proprietary vitamin B12 platform for the treatment of various forms of cancer.

4 Dec 2009

Pfizer announces a $9M cancer research collaboration in British Columbia

Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.

4 Dec 2009

Study on Helicos BioSciences' single molecule sequencing technology published

Helicos BioSciences Corporation today announced the publication of a landmark study by Dr. Bradley Bernstein of the Massachusetts General Hospital describing the use of Helicos’ single molecule sequencing technology for the performance of genome-wide, epigenomic experiments using minute amounts of nucleic acid.

4 Dec 2009

Advantages of Helicos BioSciences' single molecule sequencing technology presented

Helicos BioSciences Corporation announced today that, as previously disclosed, it has posted a presentation on its website regarding the advantages of Helicos’ single molecule sequencing technology in clinical diagnostics.

4 Dec 2009

Usefulness of heart rate variability as a diagnostic for identifying dysfunction established

According to Dr. Daniel Weiss, a recent study of heart rate autonomic markers, and cardiac mortality published in the November issue of Heart Rhythm provides additional support for the usefulness of heart rate variability as a diagnostic for identifying dysfunction (neuropathy in diabetics and others) and cardiovascular mortality, including fatal arrhythmia or sudden cardiac death.

4 Dec 2009

Wound Management Technologies to market CellerateRx within the U.S.

Wound Management Technologies, Inc., a rapidly growing provider of specialty medical products, announced today an agreement with the Health Industry Representative Association (HIRA) to serve as a non-exclusive independent sales and marketing representative to market the company's core CellerateRx® product within the U.S.

4 Dec 2009

Shorter amyloid fibres more toxic than longer counterparts, says study

A major discovery is challenging accepted thinking about amyloids - the fibrous protein deposits associated with diseases such as Alzheimer's and Parkinson's - and may open up a potential new area for therapeutics.

4 Dec 2009

BioMed Realty Trust receives additional space at Landmark under new lease agreement

BioMed Realty Trust, Inc. announced today that it has entered into a new lease with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) for approximately 131,000 square feet of additional, newly-constructed laboratory and office space at The Landmark at Eastview campus in Tarrytown, New York.

4 Dec 2009

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Alkermes, Inc. and Acceleron Pharma, Inc. today announced that Alkermes has licensed a proprietary long-acting Fc fusion technology platform, called the Medifusion™ technology, which is designed to extend the circulating half-life of proteins and peptides.

4 Dec 2009

Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed the last patient visit in its Phase 2 FDG-PET clinical trial of VIA-2291.

3 Dec 2009

NIH approves new stem cell lines for research

The National Institutes of Health announced approval of embryonic stem cell lines for federally funded research. The Washington Post reports the decision is "opening the way for millions of taxpayer dollars to be used to conduct research that was put off-limits by President George W. Bush.

3 Dec 2009

NOXXON Pharma achieves important milestone in drug discovery

NOXXON Pharma AG (NOXXON), the biopharmaceutical company focusing on the development of novel medicines based on its unique proprietary Spiegelmer® technology, announced today the achievement of an important milestone in its drug discovery and development partnership with Eli Lilly and Company.

3 Dec 2009

Medical research experts explore new strategies to speed up treatments for medical disorders

Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugural Partnering for Cures meeting.

3 Dec 2009

arGEN-X to develop its SIMPLE Antibody engine with completed EUR 12.5M Series A equity financing

arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM) platform, today announced the successful second closing of its Series A equity financing round. The Company raised an additional EUR 3.0 million (~USD 4.5 million) from two leading life science investors, Credit Agricole Private Equity and VIB (the prestigious Flemish research institute).

3 Dec 2009

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, announced today that it has entered into an option agreement with The University of Texas M. D. Anderson Cancer Center relating to an immunotherapy targeting cancer stem cells (CSCs) which has demonstrated in pre-clinical animal models significant abilities to target and destroy CSCs.

3 Dec 2009

Vertex Pharmaceuticals signs agreement to sell common stock shares

Vertex Pharmaceuticals Incorporated today announced that it has entered into an agreement to sell 11,500,000 shares of its common stock in an underwritten offering at a price to the public of $38.50 per share, which would result in aggregate gross proceeds of $442.8 million.

3 Dec 2009

Biotechnology News and Research

DCVax therapeutic cancer vaccine manufacturing process receives patent approval

APCER Pharma Solutions' webinar on 2010 FDA drug safety and pharmacovigilance initiatives

Neurologix completes Phase 2 clinical trial of Parkinson’s study

Genzyme announces reopening of enrollment in its Pompe disease ATAP program

Kyto advancing with a program for humanization of the mAbTCR23 antibody

Pfizer announces a $9M cancer research collaboration in British Columbia

Study on Helicos BioSciences' single molecule sequencing technology published

Advantages of Helicos BioSciences' single molecule sequencing technology presented

Usefulness of heart rate variability as a diagnostic for identifying dysfunction established

Wound Management Technologies to market CellerateRx within the U.S.

Shorter amyloid fibres more toxic than longer counterparts, says study

BioMed Realty Trust receives additional space at Landmark under new lease agreement

Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial

NIH approves new stem cell lines for research

NOXXON Pharma achieves important milestone in drug discovery

Medical research experts explore new strategies to speed up treatments for medical disorders

arGEN-X to develop its SIMPLE Antibody engine with completed EUR 12.5M Series A equity financing

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

Vertex Pharmaceuticals signs agreement to sell common stock shares

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News